These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 27417981)

  • 21. Longitudinal change in HbA1c in patients with type 2 diabetes: comparison of short-acting, biphasic and basal insulin.
    Rathmann W; Strassburger K; Kostev K; Schröder-Bernhardi D; Giani G; Happich M
    Exp Clin Endocrinol Diabetes; 2009 May; 117(5):230-3. PubMed ID: 19226479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in HbA1c level over a 12-week follow-up in patients with type 2 diabetes following a medication change.
    Hirst JA; Stevens RJ; Farmer AJ
    PLoS One; 2014; 9(3):e92458. PubMed ID: 24667212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes.
    Karter AJ; Parker MM; Moffet HH; Gilliam LK; Dlott R
    JAMA; 2021 Jun; 325(22):2273-2284. PubMed ID: 34077502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial.
    Arakaki RF; Blevins TC; Wise JK; Liljenquist DR; Jiang HH; Jacobson JG; Martin SA; Jackson JA
    Diabetes Obes Metab; 2014 Jun; 16(6):510-8. PubMed ID: 24298995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Use of Decomposition Methods in Real-World Treatment Benefits Evaluation for Patients with Type 2 Diabetes Initiating Different Injectable Therapies: Findings from the INITIATOR Study.
    Brekke L; Buysman E; Grabner M; Ke X; Xie L; Baser O; Wei W
    Value Health; 2017 Dec; 20(10):1252-1259. PubMed ID: 29241884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensification of antihyperglycemic therapy among patients with incident diabetes: a Surveillance Prevention and Management of Diabetes Mellitus (SUPREME-DM) study.
    Raebel MA; Ellis JL; Schroeder EB; Xu S; O'Connor PJ; Segal JB; Butler MG; Schmittdiel JA; Kirchner HL; Goodrich GK; Lawrence JM; Nichols GA; Newton KM; Pathak RD; Steiner JF
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):699-710. PubMed ID: 24639086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors and impact of intensification of antihyperglycemic therapy in type 2 diabetes: translating research into action for diabetes (TRIAD).
    McEwen LN; Bilik D; Johnson SL; Halter JB; Karter AJ; Mangione CM; Subramanian U; Waitzfelder B; Crosson JC; Herman WH
    Diabetes Care; 2009 Jun; 32(6):971-6. PubMed ID: 19228862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea.
    Barnett AH; Dreyer M; Lange P; Serdarevic-Pehar M
    Diabetes Care; 2006 Jun; 29(6):1282-7. PubMed ID: 16732009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors associated with the clinical response to nonsurgical periodontal therapy in people with type 2 diabetes mellitus.
    Michalowicz BS; Hyman L; Hou W; Oates TW; Reddy M; Paquette DW; Katancik JA; Engebretson SP;
    J Am Dent Assoc; 2014 Dec; 145(12):1227-39. PubMed ID: 25429036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IMPROVED HBA1C, TOTAL DAILY INSULIN DOSE, AND TREATMENT SATISFACTION WITH INSULIN PUMP THERAPY COMPARED TO MULTIPLE DAILY INSULIN INJECTIONS IN PATIENTS WITH TYPE 2 DIABETES IRRESPECTIVE OF BASELINE C-PEPTIDE LEVELS.
    Vigersky RA; Huang S; Cordero TL; Shin J; Lee SW; Chhabra H; Kaufman FR; Cohen O;
    Endocr Pract; 2018 May; 24(5):446-452. PubMed ID: 29847166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
    Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
    JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Cumulative Multimorbidity, Glycemic Control, and Medication Use With Hypoglycemia-Related Emergency Department Visits and Hospitalizations Among Adults With Diabetes.
    McCoy RG; Lipska KJ; Van Houten HK; Shah ND
    JAMA Netw Open; 2020 Jan; 3(1):e1919099. PubMed ID: 31922562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II).
    Bell DS; Dharmalingam M; Kumar S; Sawakhande RB
    Diabetes Obes Metab; 2011 Sep; 13(9):800-5. PubMed ID: 21477065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial.
    Vilsbøll T; Ekholm E; Johnsson E; Dronamraju N; Jabbour S; Lind M
    Diabetes Care; 2019 Aug; 42(8):1464-1472. PubMed ID: 31167892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial.
    Kennedy L; Herman WH; Strange P; Harris A;
    Diabetes Care; 2006 Jan; 29(1):1-8. PubMed ID: 16373887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study).
    Rosenstock J; Hollander P; Bhargava A; Ilag LL; Pollom RK; Zielonka JS; Huster WJ; Prince MJ
    Diabetes Obes Metab; 2015 Aug; 17(8):734-41. PubMed ID: 25931141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.